Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer

Cancer

Volumn 116, Issue 9, 2010, Pages 2132-2139

  Chadha, Manpreet K ^a   Tian, Lili ^a   Mashtare, Terry ^a   Payne, Valencia ^a   Silliman, Carrie ^a   Levine, Ellis ^a   Wong, Michael ^a   Johnson, Candace ^a   Trump, Donald L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Calcitriol; Dexamethasone; Phase 2 trial; Prostatic neoplasm

Indexed keywords

CALCITRIOL; CREATININE; DEXAMETHASONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG MEGADOSE; DYSPNEA; ECHOGRAPHY; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; LABORATORY TEST; MALE; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; THORAX PAIN; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITRIOL; CALCIUM; CREATININE; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETREATMENT;

EID: 77951462234     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24973     Document Type: Article

References (44)

1. Jemal A, Seigal R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Lin AM, Small EJ. Prostate cancer update: 2007. Curr Opin Oncol. 2008;20:294-299.
3. Sharifi N, Dahut WL, Figg WD. Secondary hormonal therapy for prostate cancer: what lies on the horizon?BJU Int. 2008;101:271-274.
4. Harris KWV, Bok RA, Kakefuda M, et al. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002;168:542-545. (Pubitemid 34793290)
5. Osborn JL, Smith DC, Trump DL. Megestrol acetate in the treatment of hormone refractory prostate cancer. Am J Clin Oncol. 1997;20:308-310. (Pubitemid 27221056)
6. Smith D, Redman BG, Flaherty LE, et al. A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer. Urology. 1998;58:257-260. (Pubitemid 28357829)
7. Santen RJ, Petroni GR, Fisch MJ, et al. Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer. 2001;92:2095-2101.
8. Reichekl H. Koeffler HP, Norman AW. The role of vitamin D endocrine system in health and disease. N Engl J Med. 1989;320:980-991. (Pubitemid 19101616)
9. McElwain MC, Dettlebach MA, Modezelewski RA, et al. Antiproliferative effects in vitro and in vivo of 1,25-dihydroxyvitamin D3 and a vitamin D3 analog in a squamous cell carcinoma model system. Mol Cell Diff. 1995;3:31-50.
10. Getzenberg RH, Light BW, Lapco PE, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 1997; 50:999-1006.
11. Mangelsdorf DJ, Koeffler HP, Donaldson CA, Pike JW, Haussler MR. 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol. 1984;98:391-398. (Pubitemid 14196456)
12. Colston KW, Chander SK, Mackay AG, Coombes RC. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol. 1992;44:693-702.
13. Shabahang M, Buras RR, Davoodi F, et al. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihyroxyvitamin D3. Cancer Res. 1994;54:4057-4064. (Pubitemid 24980073)
14. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxy-vitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994;54:805-810. (Pubitemid 24068341)
15. McGuire TF, Trump DL, Johnson CS. Vitamin D3-induced apoptosis of murine squamous cell carcinoma cells: selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem. 2001;276:26365-26373. (Pubitemid 37412854)
16. Zhou JY, Norman AW, Chen DL. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci U S A. 1990;87:3929-3932.
17. Modzelewski RA. Apoptotic effects of paclitaxel and calcitriol in rat Dunning MLL and human PC-3 prostate tumor cells in vitro. Proc Am Assoc Cancer Res. 1999;40:580.
18. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21 (Waf1/Cip1) in vitro and in vivo. Cancer Res. 1999;59:2644-2649.
19. Bernardi RJ, Trump DL, Yu W-D, McGuire TF, Hershberger PA, Johnson CS. Combination of 1alpha,25-dihydroxyvitamin D3 with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res. 2001;7:4164-4173.
20. Wang QM, Jones JB, Studzinski GP. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res. 1996;56:264-267.
21. Yu WD, McElwain MC, Modzelewski RA, et al. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst. 1998;90:134-141.
22. Klein RG, Arnaud SB, Gallagher JC, Deluca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisolism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest. 1997;60:253-259.
23. Trump DL, Potter DM, Muindi J, et al. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer. 2006;106:2136-2142.
24. Fakih MG, Trump DL, Muindi JR, et al. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res. 2007;13:1216-1223. (Pubitemid 46424063)
25. Weitzman AL, Shelton G, Zuech N, et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol. 2000;163:834-837. (Pubitemid 30091627)
26. Petrylak DP. Docetaxel for the treatment of hormone-refractory prostate cancer. Rev Urol. 2003;5(suppl 3):S14-S21.
27. National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program. National Cancer Institute Common Toxicity Criteria, version 3.0. Bethesda, Md: Available at: https://webapps.ctep.nci.nih.gov/webobjs/ctc/ webhelp/welcome-to-ctcae.htm Accessed on January 12. 2009.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92: 205-216.
29. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467. (Pubitemid 29517916)
30. Kepner JL, Chang MN. Samples of exact k-stage group sequential designs for phase II and pilot studies. Control Clin Trials. 2004;25:3-5.
31. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
32. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer; 2000.
33. Luscombe CJ, Fryer AA, French ME, et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet. 2001;358:641-642.
34. Miller GJ. Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev. 1998-1999;17:353-3360.
35. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer. 2002;94:1867-1875.
36. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451-459.
37. Giovanucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007; 121:1571-1578. (Pubitemid 47328718)
38. Woo TC, Choo R, Jamieson M, Chander S, Vieth R. Pilot study: potential role of vitamin D (cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer. 2005;51:32-39.
39. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol. 1998;159:2035-2039.
40. Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol. 1995;1:195-198.
41. Beer TM, Munar M, Henner WD. A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer. 2001;91: 2431-2439. (Pubitemid 32552832)
42. Morris MJ, Smaletz O, Solit D, et al. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer. 2004;100:1868-1875. (Pubitemid 38529564)
43. Muindi JR, Peng Y, Potter DM, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther. 2002;72:648-659. (Pubitemid 36021004)
44. Muindi JR, Johnson CS, Trump DL, Christy R, Engler KL, Fakih MG. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009;65:33-40.